Pregled bibliografske jedinice broj: 672231
Should the National strategy for the first-line treatment of H. pylori infection be changed?
Should the National strategy for the first-line treatment of H. pylori infection be changed? // Helicobacter, 18, Suppl.1. / David Y Graham (ur.).
Madrid, Španjolska: John Wiley & Sons, 2013. str. 129-129 (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 672231 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Should the National strategy for the first-line treatment of H. pylori infection be changed?
Autori
Katicic, Miroslava ; Kanizaj Filipec, Tajana ; Skurla, Bruno ; Prskalo, Marija ; Mrzljak, Anna ; Sobocan, Nikola ; Bradic, Tomislav ; Borcic, Tina ; Skrtic, Anita ; Maricic, Vladimir ; Plecko, Vanda
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Helicobacter, 18, Suppl.1.
/ David Y Graham - : John Wiley & Sons, 2013, 129-129
Skup
XXVIth International Workshop on Helicobacter and Related Bacteria in Chronic Digestive Inflammation and Gastric Cancer
Mjesto i datum
Madrid, Španjolska, 12.09.2013. - 15.09.2013
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
national strategy; sequential therapy; triple therapy
Sažetak
Background: Randomized controlled trials (RCT) and meta analyses have shown, in countries with primary resistance of H. pylori to clarithromycin higher than 20%, the Sequential treatment as the first-line therapy to be superior in efficacy than classic triple therapy. Aim: To evaluate whether the National Strategy for the first-line treatment of H. pylori infection in the Republic of Croatia should be changed. Methods: In a period between 2008 and 2010, at the Croatian Reference Centre for H. pylori infections, covering the northern and western areas of Croatia, 269 patients were treated by 10-days triple therapy (128 by IPP-A-Cl ; 141 by IPP-M-Cl). Primary resistance to macrolides was 23, 9% and to metronidazole - 37, 9%. In a period between 2011 and 2013, 53 patients were treated with sequential therapy. Primary resistance to macrolides over this period was nearly similar - 22.2%, and 37, 9% to metronidazole. Results: Success of triple therapy in the first period was unsatisfactory: IPP-A-C: 103/128=80, 5%: IPP-A-M: 110/141=78% (PP analysis). The success of sequential treatment in the last period was 50/53=94, 3% (PP analysis), which was statistically significantly higher than in the previous period (IPP-A-C vs Sequential p<0.02 ; IPP-A-M vs Sequential p<0.01). Similar results were achieved at another Centre covering the area of south Croatia. Conclusion: The Croatian Consensus Conference on H. pylori infection was held at the beginning of 2013. In our opinion, the results stated above and literature data lend support to our conclusion that, in the absence of culture results, Sequential therapy should be used as the standard first-line treatment for H. pylori infection in our country. :
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
108-0000000-3114 - HELICOBAKTER PYLORI INFEKCIJA - EVOLUCIJA BOLESTI I NOVI TERAPIJSKI POSTUPCI (Katičić, Miroslava, MZOS ) ( CroRIS)
108-1080114-0014 - Molekularna detekcija mikroorganizama: utjecaj na uporabu antimikrobnih lijekova (Plečko, Vanda, MZOS ) ( CroRIS)
108-1081873-1893 - Prognostički faktori, dijagnostika i terapija hemoblastoza (Jakšić, Branimir, MZOS ) ( CroRIS)
Ustanove:
Klinička bolnica "Merkur",
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb,
PLIVA HRVATSKA d.o.o.
Profili:
Tomislav Bradić
(autor)
Anna Mrzljak
(autor)
Marija Prskalo
(autor)
Vanda Plečko
(autor)
Nikola Sobočan
(autor)
Miroslava Katičić
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Scopus
- MEDLINE